Trial Nickname: ATLAS-2M
Full Name: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
Participant Overview: This study will divide subjects into two groups. Group 1 will include subjects receiving current ART standard of care therapy, Group 2 will include subjects currently receiving long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) in the current ATLAS study. Both groups will be randomized to receive CAB LA + RPV LA in either four-week or eight-week intervals.
Major Eligibility Criteria:
•At least 18 years old
•Currently suppressed viral load for longer than 6 months on the first treatment regimen
This study will evaluate the safety and effectiveness of switching to long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) administered every eight weeks compared to CAB LA + RPV LA administered every four weeks (Q4W) over a 48-week treatment period in approximately 1,020 adult HIV-1 infected subjects. Participants will receive injections of the medication every four or eight weeks onsite at CRI’s research facility in Boston.
Study Sponsor: ViiV Healthcare
For more information, please contact: Our Research Team, 617.502.1707 or [email protected]
*Please note this Clinical Trial and Summary was started while AccessHealth MA was still known as Community Research Initiative (CRI). This information is still relevant.Contact our Research Team